Italy’s Recordati Said to Weigh Options Amid Asian InterestBy , , and
Family-owned drugmaker has market value of 6.1 billion euros
Recordati may attract interest from other pharmaceutical firms
Family-owned Italian drugmaker Recordati SpA is exploring strategic options that may lead to a sale amid potential interest from Asian buyers, according to people with knowledge of the matter.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.